Skip to main content
S&P 5007,790.72-0.36%DOW51,068.67-0.88%NASDAQ27,490.61-0.40%BTC$83,284.00-3.18%ETH$2,564.34-5.39%GOLD$4,134.50-1.26%OIL$89.17-0.30%
Smart Investors Daily
SID Premium
IN

NASDAQ · INDV

Indivior PLC

Healthcare · Drug Manufacturers - Specialty & Generic

$35.90

Up+$0.23 (+0.65%)

Updated Oct 7, 2026, 3:53 PM

SID Score

5.6/10

Composite research score

Smart Money

62/100

Neutral

Market cap
4.47B
P/E ratio
26.96
Dividend yield
0.00%
52-week range
$27.68 – $42.81
Volume
2.39M
Avg. volume
2.19M

Price performance · INDV

INDV price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 6, 2026

INDV closed at $35.90 after 21 trading sessions, up 4.60% for the selected period.

Last close
$35.90
Period change
+4.60%
Period low
$34.22
Period high
$36.88
Daily close
View OHLC price history
INDV OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 6, 2026$35.96$36.1483$35.03$35.902.39M
Oct 5, 2026$36.00$36.2567$35.7301$35.993M
Oct 2, 2026$35.46$36.15$35.26$35.711.67M
Oct 1, 2026$35.85$36.205$35.25$35.381.88M
Sep 30, 2026$36.54$36.60$35.79$35.851.67M
Sep 29, 2026$36.74$37.05$36.08$36.592.01M
Sep 28, 2026$35.50$36.96$35.4259$36.881.17M
Sep 25, 2026$35.90$36.22$35.72$35.821.1M
Sep 24, 2026$35.71$36.28$35.57$36.002.22M
Sep 23, 2026$36.23$36.90$35.78$35.911.06M
Sep 22, 2026$35.53$36.63$35.48$36.192.22M
Sep 21, 2026$35.00$35.63$34.77$35.531.3M
Sep 18, 2026$35.59$35.615$34.59$34.884.68M
Sep 17, 2026$34.76$35.90$34.47$35.692.69M
Sep 16, 2026$33.97$34.54$33.84$34.351.87M
Sep 15, 2026$34.59$34.59$33.74$34.222.7M
Sep 14, 2026$34.74$35.01$34.15$34.473.43M
Sep 11, 2026$34.49$34.8299$34.23$34.491.3M
Sep 10, 2026$34.58$34.87$34.035$34.511.32M
Sep 9, 2026$34.32$34.795$33.92$34.771.35M
Sep 8, 2026$34.35$34.8399$33.84$34.321.82M

Latest INDV news

The latest Smart Investors Daily articles mentioning INDV.

Stock researchCompany · Overview

INDV research

Overview

Company profile and research snapshot.

Company profile

Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs for treatment of substance use disorders and other serious mental illnesses. Its products include, Sublocade, Perseris, Suboxone, Opvee among others. The vast majority of Indivior's revenue is generated in the United States, followed by United Kingdom and the rest of the world.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$38.00
Implied upside
—
Analysts
—
INDV recent ratings
DateFirmRatingTarget
Aug 5, 2026BarclaysOverweight—
Jun 18, 2026BarclaysOverweight—
Jan 12, 2026HC Wainwright & Co.Buy—
Oct 31, 2025Piper SandlerOverweight—
Oct 30, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 17, 2026

Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend

Payment of Special Dividend Contingent upon Closing of the Pending Merger TransactionRICHMOND, Va., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) (“Indivior”) today announced that its Board of Directors declared a special cash dividend (the "Special Dividend") in the amount of (i) $8.13 per share of Indivior common stock payable to holders of record of the issued and outstanding Indivior common stock as of October 30, 2026 (the “Special Dividend Record Date”) (

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By